title: Experiences with ACE inhibitors early after acute myocardial infarction. Rationale and design of the German Multicenter Study on the Effects of Captopril on Cardiopulmonary Exercise parameters post myocardial infarction (ECCE).
abstract: Left ventricular damage by necrosis of myocardial tissue can lead to compromise of left ventricular function, to left ventricular volume increase and ultimately to development of heart failure. This sequence in the pathophysiology has been shown to be blunted by ACE inhibitors. Volume increase, however, can also be helpful in restoring stroke volume and ameliorate elevation of filling pressures. Furthermore, very early institution of ACE inhibition has failed to improve short-term mortality after myocardial infarction in one large trial. The aim of the ECCE trial therefore is, to investigate the early effects of the ACE inhibitor captopril on compromise of exercise capacity, thought to be a first measurable sign of developing heart failure. The ECCE trial is a randomized, seven-center investigation, studying the effects of ACE inhibition on oxygen uptake in a double blind, placebo controlled design in a group of 204 patients. Sample size was calculated on the basis of a pilot trial. The study design and first not unblinded data of 104 patients are presented. The population consists of predominantly male patients with mostly first myocardial infarction. They were admitted to hospital within five hours of onset of chest pain. End-diastolic volumes were normal, but ejection fraction was moderately compromised. ACE inhibition was started after the first day, but within 72 hours of onset of chest pain. After four and after twelve weeks, oxygen uptake was considerably below expected values and one third of the patients had severe compromise of exercise capacity.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.forename: F X
authors.initials: FX
authors.lastname: Kleber
authors.forename: I
authors.initials: I
authors.lastname: Reindl
authors.forename: M
authors.initials: M
authors.lastname: Wenzel
authors.forename: P
authors.initials: P
authors.lastname: Rodewyk
authors.forename: S
authors.initials: S
authors.lastname: Beil
authors.forename: B
authors.initials: B
authors.lastname: Kosloswki
authors.forename: W
authors.initials: W
authors.lastname: Doering
authors.forename: G V
authors.initials: GV
authors.lastname: Sabin
authors.forename: S
authors.initials: S
authors.lastname: Hinzmann
authors.forename: U J
authors.initials: UJ
authors.lastname: Winter
mesh_terms: D000328:Adult; D000368:Aged; D002216:Captopril / Q000008:administration & dosage* / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005080:Exercise Test / Q000187:drug effects*; D005260:Female; D005500:Follow-Up Studies; D006333:Heart Failure / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D006439:Hemodynamics / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D010100:Oxygen / Q000097:blood; D010865:Pilot Projects; D012008:Recurrence; D015996:Survival Rate
chemical_list: D002216:Captopril; D010100:Oxygen